MA-based Accent Therapeutics secures $75M in series C round funding. The financing was led by Mirae Asset Capital Life Science, with participation from other new investors, Mirae Asset Capital, Mirae Asset Venture Investment, Bristol Myers Squibb and Johnson & Johnson Innovation – JJDC, Inc.
Read also – MA-based 3Daughters Secures Over $2M in Seed Funding
Proceeds from the financing will be used to support the advancement of both lead programs –Accent’s first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor – through early clinical development including safety, pharmacokinetics and early efficacy studies.
Shakti Narayan, PhD, JD, CEO of Accent Therapeutics said, “We are delighted to announce the backing of an exceptional investor syndicate who share our commitment to advancing innovative therapies for patients with cancer, These additional resources position us well to file INDs this year for both our DHX9 and KIF18A programs, and to rapidly progress them through early clinical development.”
Accent is developing therapeutics for both novel and known, but suboptimally-addressed, high-impact oncology targets with the potential to benefit large patient populations.
Read also – CA-based PowerSchool Acquired Allovue
The company’s DHX9 inhibitor seeks to address indications with high unmet need, including BRCA loss of function cancers (breast, ovarian), mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) cancers (colorectal, endometrial, gastric) and additional undisclosed cancer types.
Naveen Krishnan, MD, MPhil, of Mirae Asset Capital Life Science said, “Accent’s focus on targeting cancer cell vulnerabilities in a specific and robust way really stood out as we were evaluating companies for our first investment, They have assembled an incredible team with a successful track record of drug development, and we are excited to partner with the other seasoned investors to support Accent at this pivotal time.”
About Accent Therapeutics
Accent Therapeutics is pioneering a new class of small molecule precision cancer therapies targeting critical intracellular dependencies that span multiple types of cancer.
Read also – R.I.-based Bolden Therapeutics, Inc. Secures $1.5M in Pre-Seed Convertible Note Funding
Building upon industry-leading expertise in RNA-modifying proteins (RMPs) and the systematic mapping of both the RMP space and adjacent high-value areas for drug discovery, the company is building a flexible model that allows for a diversity of approaches to developing potentially transformative biomarker-driven cancer medicines.
